search
Wegovy
Trends
- 1
A new study suggests that people who discontinue GLP-1 medications, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings add to ongoing debate about how long patients should stay on these widely used weight-loss and diabetes drugs, and whether the cardiovascular benefits persist after stopping treatment.
- 2
GLP-1 weight-loss drugs such as Ozempic and Wegovy are reshaping sleep medicine, with clinicians reporting improved sleep apnea symptoms in patients losing significant weight and drugmakers seeking apnea indications. Sleep specialists are debating whether medication could reduce reliance on CPAP machines, while researchers caution that long-term effects on sleep disorders remain largely unstudied.
- 3Weight-loss jab maker sponsors Vogue World, drawing criticism▼‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event
Critics are raising concerns after Novo Nordisk, the maker of the weight-loss injection Wegovy, sponsored Vogue World, a high-profile fashion event tied to Vogue magazine. Commentators have called the partnership 'problematic', arguing that a pharmaceutical weight-loss company backing a leading fashion publication risks glamorising slimming drugs and reinforcing pressure around body image at a time when such jabs are already controversial.
- 4GLP-1 drugs, mental health and exercise in menopause examined▼GLP-1's and mental health; exercise and menopause
Public health coverage is drawing together two related topics: the possible mental health effects of GLP-1 weight-loss and diabetes drugs, and the role of exercise for women going through menopause. Listeners are weighing reported mood changes linked to GLP-1 medications against growing evidence that physical activity can ease menopause symptoms such as hot flashes, sleep problems and weight gain.